MedTrace Logo

Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis

NCT06763835 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2025-01-14

No results posted yet for this study

Summary

The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is

• Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.

Conditions

  • Plaque Rupture
  • Acute Coronary Syndromes

Interventions

DIAGNOSTIC_TEST

Blood is drawn to test for specific biomarkers

After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Sponsors & Collaborators

  • Xuebo Liu

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-07-30
Completion
2026-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06763835 on ClinicalTrials.gov